The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer
Abstract
Background: Prostate cancer gene 3 (PCA3) encodes a prostate-specific mRNA that has shown promise as a prostate cancer diagnostic tool. This report describes the characterization of a prototype quantitative PCA3-based test for whole urine. Methods: Whole-urine specimens were collected after digital rectal examination from 3 groups: men scheduled for prostate biopsy (n = 70), healthy men (<45 years of age with no known prostate cancer risk factors; n = 52), and men who had undergone radical prostatectomy (n = 21). PCA3 and prostate-specific antigen (PSA) mRNAs were isolated, amplified, and quantified by use of Gen-Probe DTS400® Systems. Prostate biopsy results were correlated with the PCA3/PSA mRNA ratio, and PSA mRNA concentrations were used to normalize PCA3 signals and confirm the yield of prostate-specific RNA. Assay precision, specimen stability, and mRNA yield were also evaluated. Results: The specimen informative rate (fraction of specimens yielding sufficient RNA for analysis) was 98.2%. In this clinical research study, ROC curve analysis of prebiopsy specimens yielded an area under the curve of 0.746; sensitivity was 69% and specificity 79%. Serum PSA assay specificity was 28% for this same group. PCA3 and PSA mRNAs were undetectable in postprostatectomy specimens except for one man with recurrent prostate cancer. Assay interrun CVs were ≤12%. Both mRNAs were stable in processed urine up to 5 days at 4 °C and after 5 freeze–thaw cycles. Conclusion: The APTIMA® PCA3 assay combines simple specimen processing with precise assays and existing instruments and could add specificity to the current algorithm for prostate cancer diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Bussemakers, M. J. G., van Bokhoven, A., Verhaegh, G. W. C. T., Smit, F. P., Karthaus, H. F. M., Schalken, J. A., Debruyne, F. M. J., Ru, N., & Isaacs, W. B. (1999) · PubMed · Cited by 1,051
DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer
Hessels, D., Klein Gunnewiek, J. M. T., van Oort, I., Karthaus, H. F. M., van Leenders, G. J. L., van Balken, B., Kiemeney, L. A., Witjes, J. A., & Schalken, J. A. (2003) · European Urology · doi:10.1016/s0302-2838(03)00201-x · Cited by 704
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.
de Kok, J. B., Verhaegh, G. W. C. T., Roelofs, R., Hessels, D., Kiemeney, L. A. L. M., Aalders, T. W., Swinkels, D. W., & Schalken, J. A. (2002) · PubMed · Cited by 678
uPM3, a new molecular urine test for the detection of prostate cancer
Fradet, Y., Saad, F., Aprikian, A., Dessureault, J., Elhilali, M., Trudel, C., Mâsse, B., Piché, L., & Chypre, C. (2004) · Urology · doi:10.1016/j.urology.2004.03.052 · Cited by 182
Characterization of the Prostate-specific Antigen gene: A novel human kallikrein-like gene
Riegman, P. H. J., Vlietstra, R. J., van der Korput, J. A. G. M., Romijn, J. C., & Trapman, J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92409-1 · Cited by 160
DNA-based detection of prostate cancer in urine after prostatic massage
Goessl, C. D., Müller, M., Heicappell, R., Krause, H., Straub, B., Schrader, M. G., & Miller, K. (2001) · Urology · doi:10.1016/s0090-4295(01)01268-7 · Cited by 158
Ylikoski, A. I., Sjöroos, M., Lundwall, Å., Karp, M. T., Lövgren, T. N.-E., Lilja, H. G., & Iitiä, A. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.9.1397 · Cited by 39
The role of prostate needle biopsy in evaluation of chemopreventive agents
Marks, L. S., Epstein, J. I., & Partin, A. W. (2001) · Urology · doi:10.1016/s0090-4295(00)00972-9 · Cited by 4
Self-citation
Cited by
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bedognetti, D., Batra, S. K., Haris, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01543-7 · Cited by 819
Hanke, M., Hoefig, K., Merz, H., Feller, A. C., Kausch, I., Jocham, D., Warnecke, J. M., & Sczakiel, G. (2010) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.01.027 · Cited by 638
Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M. B., Valeri, N., & Hahne, J. C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00717-x · Cited by 606
Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets
Chandra Gupta, S., & Nandan Tripathi, Y. (2017) · International Journal of Cancer · doi:10.1002/ijc.30546 · Cited by 527
Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy
Haese, A., de la Taille, A., van Poppel, H., Marberger, M., Stenzl, A., Mulders, P. F. A., Huland, H., Abbou, C.-C., Remzi, M., Tinzl, M., et al. (2008) · European Urology · doi:10.1016/j.eururo.2008.06.071 · Cited by 455
Metadata
- Authors
- Groskopf, J., Aubin, S. M., Deras, I. L., Blase, A., Bodrug, S., Clark, C., Brentano, S., Mathis, J., Pham, J., Meyer, T., Cass, M., Hodge, P., Macairan, M. L., Marks, L. S., & Rittenhouse, H.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-06-01
- Volume
- 52
- Issue
- 6
- Pages
- 1089-1095
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2097876373
- Cited by
- 529
- References
- 9
- FWCI
- 19.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.